1. Home
  2. PLSM vs NRSN Comparison

PLSM vs NRSN Comparison

Compare PLSM & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLSM

Pulsenmore Ltd. Ordinary Shares

N/A

Current Price

$6.03

Market Cap

25.0M

Sector

Health Care

ML Signal

N/A

Logo NeuroSense Therapeutics Ltd.

NRSN

NeuroSense Therapeutics Ltd.

HOLD

Current Price

$0.78

Market Cap

25.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLSM
NRSN
Founded
2014
2017
Country
Israel
Israel
Employees
63
16
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.0M
25.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PLSM
NRSN
Price
$6.03
$0.78
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
1.8M
140.2K
Earning Date
03-30-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$583.67
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.00
$0.63
52 Week High
$12.97
$2.19

Technical Indicators

Market Signals
Indicator
PLSM
NRSN
Relative Strength Index (RSI) 69.23 47.47
Support Level $3.49 $0.68
Resistance Level $6.64 $0.86
Average True Range (ATR) 0.88 0.07
MACD 0.22 0.00
Stochastic Oscillator 27.69 37.82

Price Performance

Historical Comparison
PLSM
NRSN

About PLSM Pulsenmore Ltd. Ordinary Shares

Pulsenmore Ltd is an emerging medical device company engaged in the research, development, manufacturing, marketing, and sale of non-invasive portable ultrasound solutions for home use. Its products include the Pulsenmore ES and Pulsenmore FC, along with the early-stage Pulsenmore MC, collectively referred to as Pulsenmore Products, enabling remote ultrasound scans in gynecology and other fields such as pulmonary, cardiology, and urology through telemedicine. The Company operates in a single segment focused on developing and commercializing portable ultrasound technologies, with Israel contributing the majority of its revenue.

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Share on Social Networks: